Literature DB >> 19841151

Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.

Marçal Mariné1, F Javier Pastor, Josep Guarro.   

Abstract

We evaluated the efficacy of posaconazole against Candida tropicalis in a systemic infection model with immunosuppressed mice. Posaconazole at 50 mg/kg of body weight/day prolonged the survival of mice and reduced the fungal tissue burden of mice infected with any of the five strains tested, with the exception of one strain that had a high MIC against this drug. Our results demonstrate the efficacy of posaconazole in the treatment of invasive murine infection caused by C. tropicalis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19841151      PMCID： PMC2798508          DOI： 10.1128/AAC.01136-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  C Viscoli; C Girmenia; A Marinus; L Collette; P Martino; B Vandercam; C Doyen; B Lebeau; D Spence; V Krcmery; B De Pauw; F Meunier
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

2.  International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.

Authors:  Farkad Ezzet; David Wexler; Rachel Courtney; Gopal Krishna; Josephine Lim; Mark Laughlin
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Risk Factors for Candida tropicalis fungemia in patients with cancer.

Authors:  D P Kontoyiannis; I Vaziri; H A Hanna; M Boktour; J Thornby; R Hachem; G P Bodey; I I Raad
Journal:  Clin Infect Dis       Date:  2001-09-24       Impact factor: 9.079

Review 5.  Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.

Authors:  Michele I Morris
Journal:  Am J Health Syst Pharm       Date:  2009-02-01       Impact factor: 2.637

6.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species.

Authors:  G Sóczó; G Kardos; P M McNicholas; E Balogh; L Gergely; I Varga; B Kelentey; L Majoros
Journal:  J Antimicrob Chemother       Date:  2007-09-17       Impact factor: 5.790

8.  Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus.

Authors:  M Mar Rodríguez; F Javier Pastor; Carolina Serena; Josep Guarro
Journal:  J Antimicrob Chemother       Date:  2008-12-02       Impact factor: 5.790

9.  Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; J F Meis; I M Gould; W Fu; A L Colombo; E Rodriguez-Noriega
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  2 in total

1.  Experimental therapy with azoles against Candida guilliermondii.

Authors:  Marta Sanchis; Francisco Javier Pastor; Javier Capilla; Deanna A Sutton; Annette W Fothergill; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

Review 2.  An Update on Candida tropicalis Based on Basic and Clinical Approaches.

Authors:  Diana L Zuza-Alves; Walicyranison P Silva-Rocha; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2017-10-13       Impact factor: 5.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.